Active substance
Results for the substance cemiplimab
1 result
About this active substance
Cemiplimab is a monoclonal antibody used for the treatment of certain types of cancer, including advanced or metastatic cutaneous squamous cell carcinoma. It works by blocking the PD-1 (programmed death-1) receptor, thereby stimulating the immune system to recognize and destroy cancer cells.
The medication is administered intravenously, usually once every few weeks, under the supervision of an oncology specialist. The dosage and frequency of administration are adjusted based on the patient's response and tolerance to the treatment.
Patients should be closely monitored during treatment to detect potential side effects, such as immune-related reactions, organ inflammation, or allergic reactions. It is important for patients to inform their doctor of any unusual symptoms.
Common side effects include fatigue, nausea, diarrhea, skin rashes, and joint pain. In rare cases, severe immune-related reactions such as pneumonitis, hepatitis, or colitis may occur. Patients should be informed of these risks before starting treatment.
The medication is administered intravenously, usually once every few weeks, under the supervision of an oncology specialist. The dosage and frequency of administration are adjusted based on the patient's response and tolerance to the treatment.
Patients should be closely monitored during treatment to detect potential side effects, such as immune-related reactions, organ inflammation, or allergic reactions. It is important for patients to inform their doctor of any unusual symptoms.
Common side effects include fatigue, nausea, diarrhea, skin rashes, and joint pain. In rare cases, severe immune-related reactions such as pneumonitis, hepatitis, or colitis may occur. Patients should be informed of these risks before starting treatment.